When cancer metastasizes and spreads throughout the body, it can severely change the prognosis of the disease. It is estimated that metastasis is responsible for 90 percent of cancer deaths.
University of Chicago Medicine investigators have found a new way to slow the metastasis of colon cancer: by treating it with a small molecule that essentially locks up cancer cells’ ability to change shape and move throughout the body.
In a mouse model, the molecule cut the rate of cancer metastasis in half. Though more research is needed, the result could ultimately become a new therapy that, when combined with radiation and chemotherapy, could help provide better outcomes for several types of cancer.
“It’s a very promising approach,” said Ronald Rock, PhD, Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Chicago and co-author of the paper. “It appears to be broadly applicable. If you can improve outcomes by 5 or 10 percent, that will help a lot of people.”
The results are published in the journal Proceedings of the National Academy of Sciences. Rock co-authored the paper with Ralph Weichselbaum, MD, Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology and Chair of the Department of Radiation and Cellular Oncology at UChicago.
“It’s a new area of cancer treatment, and we’re really excited to see how far this can go,” Weichselbaum said.
For cancer cells to disseminate from a tumor throughout the body, they must remodel their structure and increase their deformability to essentially crawl through tissue and worm their way into the bloodstream.
But Weichselbaum, whose research focuses on metastasis, wanted to find a way to stop that process in its tracks. He and Rock began to study a small molecule called 4-hydroxyacetophenone (4-HAP), which activates a protein in the cancer cell called nonmuscle myosin-2C (NM2C). That protein is one of the machines that allows the cell to deform and travel. When activated, it becomes locked in place, ensuring that the cancer cell cannot travel.
The investigators studied this process at both the molecular level and using human colon cancer tumors in a mouse model, and found that it significantly limited the cancer’s ability to metastasize to other parts of the body, while leaving healthy cells alone. The rate of metastasis was cut in half, compared to non-treated colon cancer.
The team envisions using this molecule in tandem with chemotherapy and radiation to create a more effective cancer-killing treatment.
“Using this molecule means there are fewer cancer cells traveling in the body, so they would be easier to kill with radiation or chemotherapy,” Weichselbaum said. “It we can decrease the spread, we have a better chance of curing the patient.”
The molecule could be an improvement over other treatments for metastasis, like kinase inhibitors, which are the basis of many chemotherapies. Those treatments work by targeting the enzymes that allow cancer to proliferate, but many times, cancer cells just find a workaround.
“With our approach, we’re essentially pouring sand right into the machine,” Rock said. “There’s no way for the cell to get around it. The engine is not going to run.”
Though the experiment was conducted on colon cancer, these preliminary results show that the molecule could work on several types of cancer that metastasize. Next the team hopes to find other molecules that could also inhibit NM2C to create a multi-layer approach for hindering metastasis. That’s important for up-and-coming physicians like Darren Bryan, MD, a former UChicago Medicine surgery resident and first author on the paper.
“In the future, drugs like 4-HAP will be used in patients who are at high risk for developing metastases,” he said. “I was always struck by the connections I developed with patients going through difficult new cancer diagnoses. We often have good, curative surgical therapy for localized tumors that have not metastasized. I learned early on, however, that patients with more advanced tumors that had metastasized could rarely be cured with surgery alone. Targeting the motor proteins of cells is a new approach, and with 4-HAP, we will be able to help patients to have better outcomes.”
This study, “4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis,” was supported by National Institutes of Health grants R01 GM109863 and R01 GM124272, a Cancer Center Support Grant P30CA014599, the Ludwig Foundation, a gift from the Foglia Foundation, and a Johns Hopkins Discovery Grant. Additional authors include Melinda Stack, Katarzyna Krysztofiak, Urszula Cichoń, Michael A. Beckett, Nikolai N. Khodarev, Alexander T. Pearson, Elizabeth C. Poli, Mitchell C. Posner, and Lai Xue of the University of Chicago, and Dustin G. Thomas, Alexandra Surcel, Eric S. Schiffhauer, and Douglas N. Robinson of the Johns Hopkins School of Medicine.
*** *** ***
About the University of Chicago Medicine & Biological Sciences
The University of Chicago Medicine, with a history dating back to 1927, is one of the nation’s leading academic health systems. It unites the missions of the University of Chicago Medical Center, Pritzker School of Medicine and the Biological Sciences Division. Twelve Nobel Prize winners in physiology or medicine have been affiliated with the University of Chicago Medicine. Its main Hyde Park campus is home to the Center for Care and Discovery, Bernard Mitchell Hospital, Comer Children’s Hospital and the Duchossois Center for Advanced Medicine. It also has ambulatory facilities in Orland Park, South Loop and River East as well as affiliations and partnerships that create a regional network of care. UChicago Medicine offers a full range of specialty-care services for adults and children through more than 40 institutes and centers including an NCI-designated Comprehensive Cancer Center. Together with Harvey-based Ingalls Memorial, UChicago Medicine has 1,286 licensed beds, nearly 1,300 attending physicians, about 3,200 nurses and over 1,100 residents and fellows.
Visit UChicago Medicine’s health and science news blog at www.uchicagomedicine.org/forefront.
Twitter @UChicagoMed Facebook.com/UChicagoMed
